NCT05713851 Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study Status RECRUITING Phase PHASE2/PHASE3
NCT05685394 DApagliflozin Cardiovascular Effects on Patients at End-stage REnal Disease Status RECRUITING Phase PHASE4
NCT05676684 Dapagliflozin With or Without Spironolactone for HFpEF Status COMPLETED Phase PHASE2/PHASE3
NCT05606718 Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling Status UNKNOWN Phase PHASE4
NCT05591235 Effect of Metformin, Dapagliflozin, Combination of Metformin and Pioglitazone in Patients With Type 2 Diabetes Status UNKNOWN Phase PHASE3
NCT05570305 Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria Status COMPLETED Phase PHASE2
NCT05550441 Effect of Dapagliflozin on VT in Patients With Heart Failure. Status UNKNOWN Phase PHASE4
NCT05521984 Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Status RECRUITING Phase PHASE1
NCT05505994 The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05457933 Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes Status COMPLETED Phase PHASE4
NCT05443932 Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients Status NOT_YET_RECRUITING Phase PHASE4
NCT05440591 Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes Status UNKNOWN Phase PHASE4
NCT05429593 A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet Status COMPLETED Phase PHASE1
NCT05420285 Cardiometabolic Effects of Dapagliflozin in Heart Failure With Reduced or Mildly Reduced Ejection Fraction Status UNKNOWN Phase PHASE2
NCT05418465 Huangqi Guizhi Wuwu Decoction in CKD Stage 2-4 Diabetic Nephropathy Status UNKNOWN Phase NA
NCT05345327 SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes Status RECRUITING Phase PHASE3